OBJECTIVE: Based on limited data, Candida sp. isolates from bronchoalveolar lavage (BAL) cultures in immunocompetent patients are thought to be contaminants rather than pathogens. The objective of this study was to determine the clinical significance of Candida sp. isolated from BAL cultures in critically ill trauma patients. DESIGN AND SETTING: Retrospective study in a level 1 trauma intensive care unit. PATIENTS AND PARTICIPANTS: All patients with Candida sp. isolated from BAL cultures over a 3-year period; 85 Candida positive BAL cultures from 62 patients were studied. MEASUREMENTS AND RESULTS: The primary outcomes were the incidence of Candida sp. in BAL, antifungal use, course of the possible infection, and mortality. Of 1077 BAL cultures 85 (8%) grew Candida sp., representing 64 episodes of possible Candida sp. ventilator-associated pneumonia. No colony counts exceeded the diagnostic threshold for bacterial VAP (>or=10(5) cfu/ml). Only 2 of 64 episodes (3%) were treated with systemic antifungals. Three other episodes (5%) were treated because of concomitant therapy for Candida sp. at other sites. The majority of episodes were not treated with antifungals and were considered contaminants (59/64, 92%). No patients developed subsequent candidemia, and most follow-up BALs (74%) were negative for Candida sp. Overall mortality (17%) was similar to previous patients with similar severity of injury at the study center (18%). CONCLUSIONS: The results of this study suggest that isolation of Candida sp. from BAL in quantities below the diagnostic threshold for VAP in this population does not require antifungal therapy.
OBJECTIVE: Based on limited data, Candida sp. isolates from bronchoalveolar lavage (BAL) cultures in immunocompetent patients are thought to be contaminants rather than pathogens. The objective of this study was to determine the clinical significance of Candida sp. isolated from BAL cultures in critically ill traumapatients. DESIGN AND SETTING: Retrospective study in a level 1 trauma intensive care unit. PATIENTS AND PARTICIPANTS: All patients with Candida sp. isolated from BAL cultures over a 3-year period; 85 Candida positive BAL cultures from 62 patients were studied. MEASUREMENTS AND RESULTS: The primary outcomes were the incidence of Candida sp. in BAL, antifungal use, course of the possible infection, and mortality. Of 1077 BAL cultures 85 (8%) grew Candida sp., representing 64 episodes of possible Candida sp. ventilator-associated pneumonia. No colony counts exceeded the diagnostic threshold for bacterial VAP (>or=10(5) cfu/ml). Only 2 of 64 episodes (3%) were treated with systemic antifungals. Three other episodes (5%) were treated because of concomitant therapy for Candida sp. at other sites. The majority of episodes were not treated with antifungals and were considered contaminants (59/64, 92%). No patients developed subsequent candidemia, and most follow-up BALs (74%) were negative for Candida sp. Overall mortality (17%) was similar to previous patients with similar severity of injury at the study center (18%). CONCLUSIONS: The results of this study suggest that isolation of Candida sp. from BAL in quantities below the diagnostic threshold for VAP in this population does not require antifungal therapy.
Authors: J Rello; J A Paiva; J Baraibar; F Barcenilla; M Bodi; D Castander; H Correa; E Diaz; J Garnacho; M Llorio; M Rios; A Rodriguez; J Solé-Violán Journal: Chest Date: 2001-09 Impact factor: 9.410
Authors: M el-Ebiary; A Torres; N Fàbregas; J P de la Bellacasa; J González; J Ramirez; D del Baño; C Hernández; M T Jiménez de Anta Journal: Am J Respir Crit Care Med Date: 1997-08 Impact factor: 21.405
Authors: Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards Journal: Clin Infect Dis Date: 2003-12-19 Impact factor: 9.079
Authors: Michael H Tarlowe; Andrew Duffy; Kollenkode B Kannan; Kiyoshi Itagaki; Robert F Lavery; David H Livingston; Paul Bankey; Carl J Hauser Journal: Am J Respir Crit Care Med Date: 2004-12-23 Impact factor: 21.405
Authors: Martin A Croce; Timothy C Fabian; Eric W Mueller; George O Maish; Jordy C Cox; Tiffany K Bee; Bradley A Boucher; G Christopher Wood Journal: J Trauma Date: 2004-05
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2004-12-18 Impact factor: 17.440
Authors: Marie-Soleil Delisle; David R Williamson; Martin Albert; Marc M Perreault; Xuran Jiang; Andrew G Day; Daren K Heyland Journal: Can Respir J Date: 2011 May-Jun Impact factor: 2.409
Authors: C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand Journal: Anaesthesist Date: 2010-01 Impact factor: 1.041
Authors: Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel Journal: Clin Infect Dis Date: 2015-12-16 Impact factor: 9.079
Authors: Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079